The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

Failure to recognize and resolve problems in an honest and evidence-based manner is the root cause of increasing vaccine ...

Kennedy selected a new team of medical professionals and scientists who are looking at vaccines are highly qualified.

The update covers the safety and appropriate timing of vaccinations, screening for osteoporosis, cervical cancer, skin cancer ...

GSK plc GSK announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision ...

Vaccines do much more than prevent specific diseases — their side benefits save children's lives around the world ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following ...

Traditionally, individuals asked health questions of their primary health care provider. Confidence in that provider as a source of trustworthy health ...

If I have sounded like a broken record these past months, it is because these developments in American public health are as ...

Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a quiet update ...

The CDC already recommends the RSV shot for all adults 75 and older and for people 60 and older who have health conditions that increase their risk of severe RSV. It also recommends the shot during ...

The reconstituted panel has not discussed RSV vaccination again and has already caused concern among doctors by questioning proven science around flu vaccines and childhood immunizations.